By Preeti Patel and Sophie Schmitz on Oct 3, 2016 We analyze recent changes in Germany’s pharmaceutical legislation & implications for the industry. Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to … More AMNOG and the German Reforms: What Will Change?
Pati Ladron – Client Solutions Lead at GPI Published 6th July 2016 The Chinese government launched a healthcare … More China Drug Pricing Reforms – Potential Impact of IRP?
Brexit: in or out? If you have lived in the UK for the past year, or anywhere else in the world for that matter, you are probably very familiar with the term. As one of the biggest political decisions of the 21st century, much confusion and concern has been brewing across industries with pharma being … More BREXIT: Is the pharmaceutical industry at risk?
The PR & MA environment is evolving at a fast pace and securing access at the right price remains challenging. Successful adaptation is the key to effectively succeed in this ever-changing world, however, most companies find adapting to change difficult. In this series, we will explore the principles to successful adaptation and discuss how … More Adaptability: Using Change for Competitive Advantage
How data-driven insights can be used to effectively drive decision making within price and access. How great would it be to be able to predict the future? Successful decision making ultimately depends on our ability to predict the future outcomes of today’s actions. If we could go back in time or foresee the future, … More Using Data-Driven Insights and Analytics to Drive Decision Making